Frank Azzopardi

Davis Polk advised the joint book-running managers on an SEC-registered offering by Abbott Laboratories of $650 million aggregate principal amount of 1.150% notes due 2028 and $650…

Davis Polk advised the initial purchaser in connection with a Rule 144A offering by CryoLife, Inc. of $100 million aggregate principal amount of its 4.250% convertible senior notes due 2025…

Davis Polk advised the representatives of the several underwriters in connection with an SEC-registered offering by NetApp, Inc. of $750 million aggregate principal amount of its 1.875%…

Davis Polk advised Credo Technology Group Holding Ltd on its private placement of approximately $100 million in shares of its Series D preferred stock.Credo is a leading provider of high…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a follow-on offering of 4,025,000 shares of common stock of SiTime…

Davis Polk advised the representatives of the several underwriters in connection with the SEC-registered offering of 5,980,000 shares of common stock of ChemoCentryx, Inc. (which…

Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Coupa Software Incorporated of $1.38 billion aggregate principal amount of…

Davis Polk advised the representatives of the several initial purchasers in connection with a Rule 144A offering by Palo Alto Networks, Inc. of an aggregate principal amount of $2…

Davis Polk advised the initial purchasers in a Rule 144A offering by Splunk Inc. of $1.265 billion aggregate principal amount of 1.125% convertible senior notes due 2027, including $165…

Davis Polk advised the representatives of the several underwriters, in connection with the $1.925 billion initial public offering of 77,000,000 shares of Class A common stock of Warner…